Population-based survival rates after curative surgical and non-surgical treatment of stage III NSCLC since 2017
Stage III non-small cell lung cancer (NSCLC) accounts for around 21 % of all cases of NSCLC and clinical management is challenged by the heterogeneity of the patient population [1]. In the recent ASCO guidelines, treatment including a surgical resection is recommended for a selected subgroup of patients with resectable disease and limited mediastinal nodal involv ement, while patients with unresectable disease should be offered concurrent chemoradiotherapy, followed by consolidation durvalumab in the absence of disease progression [2]. (Source: Lung Cancer)
Source: Lung Cancer - March 7, 2024 Category: Cancer & Oncology Authors: R.A.M. Damhuis, C. Dickhoff, I. Bahce, S. Senan Tags: Research Paper Source Type: research
Durvalumab in combination with chemoradiotherapy for patients with unresectable stage III non-small-cell lung cancer: Results from the phasaae 1 CLOVER study
Approximately 80 –85% of all lung cancer cases are non-small-cell lung cancer (NSCLC), with around 20–35% of patients presenting with stage III disease [1–4]. In the placebo-controlled, phase 3 PACIFIC trial (NCT02125461) of patients with unresectable, stage III NSCLC whose disease had not progressed following concurrent chemoradiotherapy (cCRT), consolidation therapy with the programmed cell death ligand-1 (PD-L1) inhibitor durvalumab significantly improved overall survival (OS) and progression-free survival (PFS), with a manageable safety profile [5,6]. (Source: Lung Cancer)
Source: Lung Cancer - March 6, 2024 Category: Cancer & Oncology Authors: Dong-Wan Kim, Byoung Chul Cho, Krishna Pachipala, Sang-We Kim, Chih-Liang Wang, Gee-Chen Chang, Myung-Ju Ahn, Rosa Alvarez, Chao-Hua Chiu, Jos é Trigo, Anna Estival, Sana D. Karam, Cathy O'Brien, Hema Gowda, Haiyi Jiang, Julie E. Bauman Source Type: research
Outcomes of patients with advanced epithelial growth factor receptor mutant lung cancer treated with first-line osimertinib who would not have met the eligibility criteria for the FLAURA clinical trial
Mutations in the epidermal growth factor receptor (EGFR) occur in approximately 20 % of North American patients with metastatic non-small cell lung cancer (NSCLC) [1]. The discovery of EGFR directed tyrosine kinase inhibitors (TKIs) has dramatically improved the outcomes of patients with EGFR mutant NSCLC [2,3]. Osimertinib is a third-generation EGFR TKI that was evaluated in F LAURA, a randomized phase three clinical trial against platinum-based chemotherapy. [4] A superior mOS of 39 months was observed. (Source: Lung Cancer)
Source: Lung Cancer - March 4, 2024 Category: Cancer & Oncology Authors: J. Connor Wells, Monica M. Mullin, Cheryl Ho, Barbara Melosky, Janessa Laskin, Ying Wang, Sophie Sun Tags: Research Paper Source Type: research
Uncommon de novo EGFRT790M-Mutant NSCLC characterized with unique genetic Features: Clinical response and acquired resistance to the third-generation EGFR-TKIs treatment
Non-small cell lung cancer (NSCLC) is the primary cause of cancer-related fatalities globally [1,2]. Identification of activating epidermal growth factor receptor (EGFR) mutations has shifted the treatment paradigm for NSCLC [3 –5]. First/second-generation EGFR-tyrosine kinase inhibitors (TKIs) have been developed and have become the standard of care in advanced NSCLC patients harboring sensitive EGFR mutation (exon 19 deletion or L858R) [5–7]. However, drug resistance would eventually happen, and secondary T790M mutat ion located at exon 20 of the EGFR gene accounts for over 50 % of the acquired resistance mechanism...
Source: Lung Cancer - March 1, 2024 Category: Cancer & Oncology Authors: Lan-Lan Pang, Wei-Tao Zhuang, Yi-Hua Huang, Jun Liao, Meng-Zhen Li, Yi Lv, Li Zhang, Wen-Feng Fang Source Type: research
Contents
(Source: Lung Cancer)
Source: Lung Cancer - March 1, 2024 Category: Cancer & Oncology Source Type: research
Describing differences among populations of thoracic tumors patients under and over 80 years: Data analysis from the SLCG thoracic tumor registry
According to the World Health Organization (WHO), lung cancer is the second most common cancer worldwide in both sexes (accounting for 11.4 % of all cancers) and the first in terms of mortality (18 % of cancer deaths). The top five causes of death in high-income countries are heart disease, stroke, lung cancer, pneumonia, and asthma/bronchitis. Due to its high mortality rate, lung cancer is considered a significant public health conc ern. (Source: Lung Cancer)
Source: Lung Cancer - February 29, 2024 Category: Cancer & Oncology Authors: Mariano Provencio, Manuel Cobo, Delvys Rodriguez-Abreu, Enric Carcereny, Alexandra Cantero, Virginia Calvo, Rafael L ópez Castro, Reyes Bernabé, Joaquim Bosch-Barrera, Bartomeu Massutí, Rosario García Campelo, Alfredo Sánchez-Hernández, Ana Laura Or Source Type: research
Describing differences among populations of thoracic tumors patients under and over 80 years: Data analysis from the SLCG thoracic tumor registry
According to the World Health Organization (WHO), lung cancer is the second most common cancer worldwide in both sexes (accounting for 11.4 % of all cancers) and the first in terms of mortality (18 % of cancer deaths). The top five causes of death in high-income countries are heart disease, stroke, lung cancer, pneumonia, and asthma/bronchitis. Due to its high mortality rate, lung cancer is considered a significant public health co ncern. (Source: Lung Cancer)
Source: Lung Cancer - February 29, 2024 Category: Cancer & Oncology Authors: Mariano Provencio, Manuel Cobo, Delvys Rodriguez-Abreu, Enric Carcereny, Alexandra Cantero, Virginia Calvo, Rafael L ópez Castro, Reyes Bernabé, Joaquim Bosch-Barrera, Bartomeu Massutí, Rosario García Campelo, Alfredo Sánchez, Ana Laura Ortega, Maria Source Type: research
Association of patient and health care organization factors with incidental nodule guidelines adherence: A multi-system observational study
Health care organizations are increasingly developing systems to ensure high levels of adherence to follow-up guidelines for the millions of people diagnosed with incidental pulmonary nodules every year [1]. Otherwise these patients may fall through the cracks and be diagnosed with more advanced stage lung cancer [2 –6]. Systems with both incidental nodule and lung cancer screening (LCS) programs may improve the proportion of people diagnosed with early stage compared to later stage lung cancer [7]. (Source: Lung Cancer)
Source: Lung Cancer - February 29, 2024 Category: Cancer & Oncology Authors: Christopher G. Slatore, Elizabeth R. Hooker, Sarah Shull, Sara E. Golden, Anne C. Melzer Source Type: research
The Danish lung cancer registry: A nationwide validation study
The Danish Lung Cancer Registry (DLCR) has monitored interventions and outcomes of all Danish patients diagnosed with lung cancer with a high level of completeness since its establishment in the year 2000 [1,2]. The aims of the DLCR are to evaluate treatment response and to compare and streamline treatment within the five administrative regions of Denmark, in order to improve lung cancer treatment and overall survival [3]. The DLCR was not initiated as a research tool, however, it has been utilized for clinical and epidemiological research in several studies [4]. (Source: Lung Cancer)
Source: Lung Cancer - February 29, 2024 Category: Cancer & Oncology Authors: Anja Gouliaev, Fatima Ali, Erik Jakobsen, Susanne O. Dalton, Ole Hilberg, Torben R. Rasmussen, Niels L. Christensen Source Type: research
Association Between Surgical Quality and Long-Term Survival in Lung Cancer
While there have been advances in screening, surgical outcomes, and novel therapies in lung cancer [1 –3], significant variations remain in both perioperative and long-term outcomes across hospitals [4–8]. Traditionally, surgical performance has been reported using perioperative process measures and risk-adjusted outcomes [9,10]. However, these measures may not be reliable in their ability to di stinguish hospital quality and only provide information regarding a limited aspect of lung cancer care [10–17]. (Source: Lung Cancer)
Source: Lung Cancer - February 25, 2024 Category: Cancer & Oncology Authors: James D. Lee, Richard Zheng, Olugbenga Okusanya, Nathaniel R. Evans, Tyler R. Grenda Source Type: research
Lung cancer detection in perioperative patients' exhaled breath with nanomechanical sensor array
The number of lung cancer deaths is the highest among all cancer types worldwide [1]. The 5-year survival rate of lung cancer decreases with the advance of the stage, from stage IA1 (92 %) to stage IVB (0 %), according to an IASLC report [2]. Therefore, it is essential to detect and treat lung cancer at an early stage. However, lung cancer is difficult to detect in its early stages because it often remains asymptomatic until more advanced stages. Although screening through low -dose computed tomography (CT) has been reported to reduce the lung cancer mortality rate, CT screening is expensive, labor intensive, and the ...
Source: Lung Cancer - February 25, 2024 Category: Cancer & Oncology Authors: Yusuke Saeki, Naoki Maki, Takahiro Nemoto, Katsushige Inada, Kosuke Minami, Ryo Tamura, Gaku Imamura, Yukiko Cho-Isoda, Shinsuke Kitazawa, Hiroshi Kojima, Genki Yoshikawa, Yukio Sato Source Type: research
Outcomes in patients treated with frontline immune checkpoint inhibition (ICI) for advanced NSCLC with KRAS mutations and STK11/KEAP1 comutations across PD-L1 levels
KRAS mutations(m) are the most common oncogenic alterations in NSCLC, occurring in 20 –40 % of lung adenocarcinomas [1–3]. While KRAS has been historically considered undruggable, two KRAS G12C inhibitors are now FDA approved [4,5] and there is a suite of emerging KRAS-directed agents in development [6]. Understanding the relative therapeutic benefit of these novel agents, as w ell as designing clinical trials with prognostic balance between arms, will require a thorough understanding of outcomes and treatment responsiveness of KRASm aNSCLC across subgroups defined by KRASm subtype, PD-L1 status, and comutations. (Source: Lung Cancer)
Source: Lung Cancer - February 23, 2024 Category: Cancer & Oncology Authors: Lova Sun, Elizabeth A. Handorf, Yunyun Zhou, Hossein Borghaei, Charu Aggarwal, Jessica Bauman Source Type: research
Phase II study investigating the efficacy and safety of glesatinib (MGCD265) in patients with advanced NSCLC containing MET activating alterations
In this Ph II study glesatinib (MET and AXL inhibitor) had acceptable safety but modest activity in NSCLC cohorts with MET dysregulation (Source: Lung Cancer)
Source: Lung Cancer - February 22, 2024 Category: Cancer & Oncology Authors: David S. Hong, Federico Cappuzzo, Byoung Chul Cho, Afshin Dowlati, Maen Hussein, Dong-Wan Kim, Ivor Percent, James G. Christensen, Jos ée Morin, Diane Potvin, Demiana Faltaos, Vanessa Tassell, Hirak Der-Torossian, Richard Chao Source Type: research
STK11/LKB1 alterations worsen the poor prognosis of KRAS mutated early-stage non-squamous non-small cell lung carcinoma, results based on the phase 2 IFCT TASTE trial
Despite recent important progresses in the diagnosis and treatment of lung cancers, it remains a leading cause of cancer death worldwide [1]. The development of targeted therapies and immune checkpoints inhibitors has significantly improved PFS and OS for patients with advanced diseases. Therapeutic options for metastatic NSCLC depend on the detection of somatic oncogenic drivers or on the level of PD-L1 expression. Tumors harboring sensitizing EGFR, BRAF, KRAS p.G12C or MET activating mutations (mut) may benefit from targeted therapy such as EGFR tyrosine kinase inhibitors (TKI), BRAF/MEK inhibitors, KRAS or MET inhibitor...
Source: Lung Cancer - February 19, 2024 Category: Cancer & Oncology Authors: Jean Baptiste Oudart, Simon Garinet, Caroline Leger, Fabrice Barlesi, Julien Mazi ères, Gaelle Jeannin, Clarisse Audigier-Valette, Denis Morot-Sibilot, Alexandra Langlais, Elodie Amour, Nathalie Mathiot, Gary Birsen, Hélène Blons, Marie Wislez Source Type: research
Lazertinib as a frontline treatment in patients with EGFR-mutated advanced non-small cell lung cancer: Long-term follow-up results from LASER201
Targeted treatment with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) is the current standard of care for EGFR-mutated advanced/metastatic non-small cell lung cancer (NSCLC), which typically exhibits a five-year survival rate of 25 –30 % [1,2]. Notably, in Asia, nearly half of the patients diagnosed with lung adenocarcinoma harbor classical activating EGFR mutations (exon 19 deletions [Ex19Del] and L858R point mutation in exon 21 [3]. Patients with these mutations were found to exhibit favorable clinical responses to first -generation EGFR TKIs [4]. (Source: Lung Cancer)
Source: Lung Cancer - February 19, 2024 Category: Cancer & Oncology Authors: Byoung Chul Cho, Ji-Youn Han, Ki Hyeong Lee, Yun-Gyoo Lee, Dong-Wan Kim, Young Joo Min, Sang-We Kim, Eun Kyung Cho, Joo-Hang Kim, Gyeong-Won Lee, Sung Sook Lee, NaMi Lee, Jang Young Wang, Hyejoo Park, Myung-Ju Ahn Source Type: research
